Table 1.
Comparison of existing drugs currently being tested for the antiviral treatment and prevention of COVID-19 through drug repurposing.
| Drug | Indication | Dosage in Individuals Aged ≥ 12 Years | Effectiveness | Side Effects | Precautions in Patients with Complications | |||
|---|---|---|---|---|---|---|---|---|
| Cardio-Pulmonary | Renal | Hepatic | Retinal[M1] | |||||
| Chloroquine | Treatment Prevention |
500–600 mg weekly | Malaria, Amebiasis, Porphyria Cutanea Tarda | Serious | Yes | Yes | Yes | Yes |
| Ivermectin | Treatment Prevention |
3–15 mg once | Parasitic infestations | Mild/Serious | No | Yes | Yes | No |
| Remdesivir | Treatment | 100–200 mg daily | Ebola, Marburg virus diseases | Mild | No | Yes | No | No |
| Sofosbuvir | Treatment | 400 mg daily | Hepatitis-C, HIV | Mild/Moderate | Yes | Yes | Yes | Yes |
| Boceprevir | Treatment | 200 mg daily | Hepatitis-C | Mild/Serious | Yes | No | Yes | Yes |
| α-Difluoromethylornithine | Treatment | 300–400 mg/kg/day, cream |
Trypanosomiasis, reduction of facial hair in women | Mild/Serious | No | No | Yes | No |